Salute e Benessere

Sihoo Launches Its Breakthrough Doro S300 Chair with the "Defy Gravity With…

The Doro S300: Defying Gravity, Redefining Comfort TheDoro S300 : Defying Gravity, Redefining Comfort At the core of the Doro S300 chair is its "Anti-Gravity Mechanism," featuring aerospace-grade glass fiber plates, a breakthrough in the industry, allowing the user to recline smoothly, stop at any angle, and return to an upright position effortlessly. Additionally, the four-axis linkage of the mechanism synchronizes the seat cushion with the backrest when the user reclines…
PR Newswire
02/02/2024

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.The Executive Leadership Team has on February 1 st, 2024 from Novozymes A/S received the allocated shares from the...
Nasdaq GlobeNewswire
02/02/2024

Pixium Vision announces the rejection of the sale plan (plan de cession) by the…

Pixium Vision announces the rejection of the sale plan ( plan de cession ) by the Court and the conversion of the receivership proceedings into liquidation proceedingsParis, France, February 2, 2024 – 02:00 p.m. (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces the decision of the Paris Commercial Court, by...
Nasdaq GlobeNewswire
02/02/2024

Bulat Utemuratov Foundation celebrates a decade serving Kazakhstan

Education and culture remain central to the Foundation's mission. Last year it funded the construction of a municipal school for 1,500 children in a suburb of Astana. Next year it will complete a public sports and cultural center of 8,500 sq m in the same area. Education and culture remain central to theFoundation's mission. Last year it funded the construction of a municipal school for 1,500 children in a suburb of Astana. Next year it will complete a public sports and cultural center of...
PR Newswire
02/02/2024

Tisotumab Vedotin Marketing Authorization Application Validated by European…

Media ReleaseCOPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq:GMAB)andPfizer, Inc.(NYSE PFE) today announced thatthe European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease...
Nasdaq GlobeNewswire
02/02/2024

Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ-001 in…

The trans-splicing ribozyme is derived from the self-splicing Tetrahymena group I intron, which both recognizes and reprograms the target RNA into the therapeutic transcript of interest. Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is catalytically capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA. Thus…
PR Newswire
02/02/2024

Wingderm® Launches Lasermach2, Revolutionizing Hair Removal Solution, at IMCAS…

Additionally, Lasermach 2 is equipped with intelligent system, Wingcloud® helps the clinic owners to manage intelligently and improve customer service. Detailed treatment data can be accessed by both operators and patients, ensuring continuous treatment, increasing patients' trust in operations. Additionally, Lasermach 2 is equipped with intelligent system, Wingcloud® helps the clinic owners to manage intelligently and improve customer service. Detailed treatment data can be accessed by both...
PR Newswire
02/02/2024

Dedicare launches Dedicare International - innovative offering for Nordic…

During the initial phase, healthcare professionals will be offered the opportunity to take assignments in the UK and the British Overseas Territories such as the Falkland Islands, Gibraltar, and St. Helena. In addition, doctors will be offered assignments in Ireland - where Dedicare UK is an approved supplier, and assignments in Australia and New Zealand - in collaboration with a company focused on relocating doctors into the country. During the initial phase, healthcare professionals will be...
PR Newswire
02/02/2024

MAXIMA GRUPĖ WITHDRAWS FROM VILNIAUS PREKYBOS PARAMOS FONDAS DABAR…

MAXIMA GRUPĖ, UAB informsthatonFebruary 1, 2024, it withdrewfromtheshareholdersofthecharity fund Vilniaus prekybos paramos fondas “Dabar”. MAXIMA GRUPĖ, UAB had been a shareholder in this charity fund since September 20, 2022. AdditionalInformation "Maxima Grupė" manages retail chains "Maxima" (in the Baltic countries), "Stokrotka" (in Poland), "T-Market" (in Bulgaria), and the online food store "Barbora," operating in the Baltic countries...
Nasdaq GlobeNewswire
02/02/2024

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully…

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completedFebruary 2, 2024Company announcement No. 07On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination") was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January…
Nasdaq GlobeNewswire
02/02/2024

Electrolux Group Year-end report Q4 2023

Highlights of the fourth quarter of 2023 Highlights of the fourth quarter of 2023 President and CEOJonas Samuelson'scomment 2023 proved to be another challenging year. High inflation, rising interest rates and geopolitical tensions continued to weigh on consumer sentiment, which remained weak in our major markets. The overall reduced purchasing power led to more consumers shifting to lower price points and postponing purchases in discretionary categories, especially impacting the...
PR Newswire
02/02/2024

THERYQ and Gustave Roussy have been selected as part of the "i-Démo" France 2030…

The first clinical FLASHDEEP device will be installed in France, at Gustave Roussy, late 2026, to conduct clinical trials with eligible patients. This system will be able to treat deep solid tumors up to 20 cm thanks to a high-energy electron beam and a dose rate a thousand times higher than that used in conventional radiotherapy. FLASHDEEP represents a major technological advancement in the fight against cancer, offering the prospect of a more effective, better tolerated, shorter, and therefore…
PR Newswire
02/02/2024

Hansa Biopharma Year-end report January-December 2023

Clinical pipeline update Clinical pipeline update Events after closing period Financial summary Søren Tulstrup, President and CEO of Hansa Biopharma, comments "Hansa enters 2024 in a strong position to successfully execute on our key priorities. I am encouraged by the performance of Idefirix ® against key launch metrics and the continued progress we have achieved across our pipeline development activities. I am particularly excited...
PR Newswire
02/02/2024

Junshi Biosciences Announces Toripalimab's NDA Accepted by the Singapore Health…

This NDA was submitted through Project Orbis, an initiative of the US Food and Drug Administration (FDA)'s Oncology Center of Excellence (OCE). Project Orbis provides a collaborative mechanism and framework between the FDA and regulatory partners in other countries and regions for concurrent submission and review of oncology drugs. At present, eight regulatory agencies have joined Project Orbis, including the FDA, the Australia Therapeutic Goods Administration (“TGA”), HSA, Health Canada...
Nasdaq GlobeNewswire
02/02/2024

Spanning 7,000 km, Toumai (TM) has completed the world's first cross-border 5G…

On site, it was evident that the remote simulation surgery verification had clear visibility throughout the process, with stable operation of the robotic arms and flexible instruments. The cutting and suturing effects were indistinguishable from local surgeries. Even in a regular 5G network environment, the Toumai™ robot demonstrated its precise identification, accurate dissection, and meticulous resection capabilities, fully showcasing the system's stability, the precision of the robotic arms…
PR Newswire
02/02/2024

NABR Files Expanded Petition Challenging the Listing of Long-Tailed Macaques by…

Prior to July 2022, long-tailed macaques were designated as "vulnerable" by the IUCN. In 2022, the IUCN revised its designation to "endangered" based upon a scientific review published by Hansen et al. (2022).1 The expanded NABR petition now calls for the IUCN to vacate both the "endangered" and "vulnerable" listings until "a new status assessment of M. fascicularis is conducted by truly independent scientists not involved in advocacy roles for the…
PR Newswire
02/02/2024

NABR Files Expanded Petition Challenging the Listing of Long-Tailed Macaques by…

Prior to July 2022, long-tailed macaques were designated as "vulnerable" by the IUCN. In 2022, the IUCN revised its designation to "endangered" based upon a scientific review published by Hansen et al. (2022).1 The expanded NABR petition now calls for the IUCN to vacate both the "endangered" and "vulnerable" listings until "a new status assessment of M. fascicularis is conducted by truly independent scientists not involved in advocacy roles for the…
PR Newswire
02/02/2024

BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT

The Company will pay a finder's fee of $57,400 in cash related to the financing. The Company will pay a finder's fee of$57,400in cash related to the financing. The Company anticipates closing the second and final tranche of the private placement no later thanFebruary 9th, 2024. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), a biopharmaceuticals company based inVancouver, Canada, is developing BVX-0918, a personalized immunotherapeutic...
PR Newswire
01/02/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 1 February 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
01/02/2024

Crossject to host a business briefing on commercial strategy on February 6 at…

Dijon, France, February 1, 2024 --18:15 CET-Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations,will hold a conference call on its commercial strategy in the U.S. and Europe on February 6, 2024 at 17:30 CET. The presentation will be held in English.Patrick Alexandre, Crossject's CEO and Executive Chairman, and Olivier Gire, COO of Specialty Pharma, will provide a business update following the...
Nasdaq GlobeNewswire
01/02/2024

EssilorLuxottica: Full-Year 2023 Results Conference Call Invitation

Full-Year 2023 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Full-Year 2023 Results Conference Call on: Wednesday, February 14, 2024, at 6:30 pm CET Dial-in telephone access:If you wish to dial into the conference call, please pre-register at...
Nasdaq GlobeNewswire
01/02/2024

Number of votings rights as of January 31 2024

Nicox SA Société anonyme with a registered capital of € 50,186,094 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On February 1st, 2024, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l'AMF) As of January 31, 2024Total number of shares...
Nasdaq GlobeNewswire
01/02/2024

Dr. Kaveh Kahen, Appointed President at Phenomenex

Most recently, Dr. Kahen served as CEO at Advion Interchim Scientific. During his tenure, he successfully led the integration of US and European entities, resulting in consecutive years of above-market growth. Kaveh is renowned for driving profitable growth in the highly competitive life sciences, analytical testing, and lab equipment markets. Most recently, Dr. Kahen served as CEO at Advion Interchim Scientific. During his tenure, he successfully led the integration of US and European...
PR Newswire
01/02/2024

Medical Lasers Market Worth $8.3 Billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229613259 Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229613259 Browse in-depth TOC on "Medical Lasers Market" 171 - Tables 39 - Figures 274 - Pages Medical Lasers Market Scope: Solid-state lasers systems segment to register significant growth rate over the forecast period of 2023-2028. Based on the technology, the global...
PR Newswire
01/02/2024
Altri  Comunicati